This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 18 print issues and online access
$259.00 per year
only $14.39 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
The datasets analysed during the current study are available in the Fame Study Group repository, https://doi.org/10.1016/j.ophtha.2010.12.028.
Reference
Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125–32. https://doi.org/10.1016/j.ophtha.2012.04.030.
Funding
No funding was provided for the development of this work.
Author information
Authors and Affiliations
Contributions
RS and PA reviewed the literature, identifying and summarising the core points. RS designed the infographic. RS and WR formatted the figure file and required forms and statements for submission. WR and PA proofread the infographic.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Singappuli, R., Abeysiri, P. & Rahman, W. Infographic: FAME (fluocinolone acetonide for macular edema) trials of ILUVIEN® vitreous sustained-delivery inserts for diabetic macular oedema. Eye (2025). https://doi.org/10.1038/s41433-025-04088-3
Received:
Revised:
Accepted:
Published:
Version of record:
DOI: https://doi.org/10.1038/s41433-025-04088-3